secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001171843-25-000114
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Profound Medical Q4 revenue up ~105-110% YoY; switches to US GAAP
-----------------------------------------------------------------

- Preliminary Q4 2024 revenue $4.1-4.2M, YoY growth 105-110%, sequential growth 45-48%.
- Preliminary FY2024 revenue $11.1-11.2M vs $7.2M in FY2023.
- As of Jan 1, 2025, transitioning from IFRS to US GAAP; will file US domestic forms (10-K, 10-Q, 8-K).
- TULSA procedure now reimbursed at Urology APC Level 7 across multiple treatment settings.
- Company to present at JPM 2025 on Jan 16 at 11:15 a.m. PT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325000114/0001171843-25-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325000114/f8k_010825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer